Item 1.01 Entry into a Material Definitive Agreement
On May 22, 2020, Vir Biotechnology, Inc. (the Company) and Biogen Inc. (Biogen) entered into a clinical development and
manufacturing agreement (the Agreement), pursuant to which Biogen will perform process development activities and specified manufacturing services under agreed statements of work for certain
pre-commercial and clinical supply of SARS-CoV-2 antibodies. Under the terms of the Agreement, the Company agreed to pay fees for
Biogens performance of services as provided in each applicable statement of work, including costs to third parties on a pass-through basis. The parties entered into three statements of work for the process development and certain clinical
manufacturing services simultaneously with the execution of the Agreement, with the cost of activities under such agreed statements of work totaling approximately $13.8 million. The Agreement includes the right for Vir to request a technology
transfer of all manufacturing technology and processes developed under the Agreement to Vir or any third party designated by Vir to conduct manufacturing of SARS-CoV-2
antibody using such technology, including applicable licenses to Vir under Biogens relevant intellectual property rights. In connection with any such technology transfer, the Company also agreed to pay an access fee to Biogen for
each successful batch of SARS-CoV-2 antibody drug substance manufactured using certain improvements relating to increases in batch yield developed under the Agreement,
whether such manufacturing is performed by the Company, its affiliates, or third parties. If the Company successfully manufactures all batches of SARS-CoV-2 antibody
drug substance for which it is currently committed under its letter agreement with Samsung BioLogics Co., Ltd. dated April 9, 2020, based on the Companys current working assumptions of manufacturing yield per batch, the access fee payable
to Biogen in connection with the Samsung manufacture will total approximately $100 million. The Company has the right to terminate the Agreement without cause upon 180 days prior written notice. Either party may terminate the Agreement
upon the other partys bankruptcy or uncured material breach.
The parties may discuss the possibility of negotiating a commercial supply agreement
for the SARS-CoV-2 antibody products, but are not obligated to do so.
The
foregoing description of the material terms of the Agreement is qualified in its entirety by reference to the full text of the Agreement, a copy of which will be filed as an exhibit to a subsequent filing with the Securities and Exchange Commission.
On May 29, 2020, the Company issued a press release announcing the transactions described above. A copy of the press release is attached to this
report as Exhibit 99.1.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend, potential and similar expressions
(as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on the Companys expectations and assumptions as of
the date of this Current Report. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this Current Report
include statements regarding the potential benefits of the Companys collaboration with Biogen, the total access fee payable to Biogen in connection the Samsung manufacture, the timing and scale of manufacturing activities, the demand for
antibody therapies, the timing of commencement of clinical trials for the Companys antibody product candidates and the Companys ability to address the current COVID-19 pandemic and future
outbreaks of the disease. Many factors may cause differences between current expectations and actual results including unexpected results during clinical trials, difficulties in obtaining regulatory approval, clinical site activation rates or
clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, delays or disruptions in the Companys business or clinical trials due to
the COVID-19 pandemic, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this
Current Report are discussed in the Companys filings with the Securities and Exchange Commission, including the section titled Risk Factors contained therein. Except as required by law, the Company assumes no obligation to update
any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.